SKP2 and prostate adenocarcinoma: The two analysis methods consistently indicated that elevated SKP2 expression represented poor OS and/or DSS for patients with ACC (adrenocortical carcinoma), KICH, KIRP, LGG (brain lower grade glioma), LIHC, MESO (mesothelioma), PRAD, SKCM (skin cutaneous melanoma), or THCA (hazard ratio [HR] > 1, p < 0.05) and favorable OS and DSS for individuals with OV (ovarian serous cystadenocarcinoma), READ, or THYM (thymoma) (HR < 1, p < 0.05) (Fig. 5A–D).